Kathleen Willcox
Family Medicine · Mount Ayr, IANPI 1205218112
Payments from drug & device makers
Across 175 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$445
- Pfizer$320
- Novo Nordisk$303
- Amgen$252
- Lilly USA, LLC$201
- Boehringer Ingelheim$196
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,77398%
- Education$582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $445 |
| Pfizer | 20 | $320 |
| Novo Nordisk | 19 | $303 |
| Amgen | 19 | $252 |
| Lilly USA, LLC | 12 | $201 |
| Boehringer Ingelheim | 12 | $196 |
| E.r. Squibb & Sons, L.L.C. | 10 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $109 |
| Merck | 6 | $91 |
| AbbVie | 6 | $90 |
| GSK | 5 | $69 |
| Kowa Pharmaceuticals America, Inc. | 5 | $64 |
| Verona Pharma, Inc. | 4 | $64 |
| Johnson & Johnson | 2 | $62 |
| Novartis | 3 | $61 |
| Astellas Pharma US Inc | 4 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $47 |
| Mylan Specialty L.p. | 3 | $39 |
| Lundbeck LLC | 2 | $35 |
| Viatris Specialty LLC | 2 | $28 |
| Abiomed | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Cranial Technologies, Inc | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
How this compares
$2,831 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 92 | $103,385 |
| JardianceEmpagliflozin | 113 | $85,910 |
| EliquisApixaban | 109 | $69,799 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $66,080 |
| MyrbetriqMirabegron | 65 | $32,832 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $32,224 |
| FarxigaDapagliflozin Propanediol | 40 | $24,436 |
| XareltoRivaroxaban | 49 | $23,264 |
| MounjaroTirzepatide | 19 | $19,658 |
| NuedextaDextromethorphan Hbr/Quinidine | 24 | $17,902 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 48 | $15,818 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $14,270 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $13,966 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $13,195 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $12,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $303 | $110,563103 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta | $196 | $106,157166 claims |
| PfizerEliquis, Abrysvo | $320 | $85,617157 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $69 | $80,632124 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $445 | $56,65981 claims |
| Astellas Pharma US IncMyrbetriq | $53 | $32,83265 claims |
| Johnson & JohnsonXarelto | $62 | $23,26449 claims |
| Lilly USA, LLCMounjaro | $201 | $19,65819 claims |
| NovartisEntresto | $61 | $9,79920 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $109 | $5,10415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Mount Ayr
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
- Carlos Alarcon SchroderJohnston$237K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.